Clinical Trial Update: Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating NiCord allogeneic stem and progenitor cells for hemoglobinopathies (sickle cell disease and thalassemia).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Thalassemia

Drugs mentioned

• NiCord (omidubicel)
• UCB-derived ex vivo expanded stem and progenitor cells

Snippet

Sponsor: Gamida Cell ltd | Conditions: Sickle Cell Disease & Thalassemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-04-27